Navigation Links
Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012
Date:1/14/2009

Recent Entrants Invest Heavily in Promotion to Capture Share in Mature Market, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that growth opportunities for Roche/Chugai's Actemra (marketed as RoActemra in Europe) will propel Roche to sixth position in the rheumatoid arthritis market by 2012. Driving factors include Actemra's early market entry into Japan, making it the only agent available for the treatment of inadequate responders to TNF-alpha in Japan until the arrival of Bristol-Myers Squibb's Orencia in 2012, and the likelihood that the drug will be used in relatively early lines of biologic therapy.

Currently, physicians rely heavily on TNF-alpha inhibitors in early lines of biological therapy, and reserve agents with other mechanisms of action, such as Orencia and Biogen Idec/Genentech's Rituxan (also marketed by Chugai and Zenyaku Kogyo in Japan, and marketed as MabThera in Europe by Roche), largely for TNF-alpha inadequate responders. According to the new report entitled Brands & Strategies: Rheumatoid Arthritis, physicians indicate that Actemra's efficacy data is compelling enough to consider using it earlier in therapy; particularly once it has been on the market long enough to gather some post-marketing data to provide reassurance about side effects such as elevated lipid levels and elevated liver enzymes.

"Despite a recent regulatory setback in the U.S., physicians are cautiously optimistic about the efficacy of Actemra," said Dancella Fernandes, Ph.D., analyst at Decision Resources. "Decision Resources anticipates the drug's uptake as a treatment for inadequate responders to TNF-alpha will garner Actemra sales of $603 million in 2012."

The report also finds despite significant increases in promotional spend coinciding with the launch of Orencia and Rituxan, these relatively new entrants are struggling to secure significant market share in the mature rheumatoid arthritis market. Promotional spending doubled and increased tenfold (for Orencia and Rituxan, respectively) in 2006 compared with 2005. While Rituxan's spend remained similar in 2007 compared to 2006, Orencia's spend increased fivefold in 2007. Despite these efforts, only one percent of surveyed rheumatologists reported that Orencia or Rituxan was the first brand that came to mind when thinking of rheumatoid arthritis treatments.

About Brands & Strategies

The Brands & Strategies report series from Decision Resources reveals what it takes to be successful in a pharmaceutical market. It offers the most comprehensive commercial analysis of the brands and strategies of competing companies, insight from physicians and patients, and forecasted impact of future events. Brands & Strategies is the first and only report series to bring together all the competitive information elements pharma companies need to better position themselves in a market and plan future strategy based on what competitors are doing.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Heather Hilty                   Elizabeth Marshall
    Decision Resources              Decision Resources, Inc.
    781-296-2536                    781-296-2563
    hhilty@dresources.com           emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Economic Uncertainty Fuels Vendormate Growth in 2008
2. Access Family Services, Inc. Makes the List for the Second Year in a Row! Access Family Services 2008 Ranks No. 2851 on the Inc. 5000 With Three-Year Sales Growth of 128%
3. Growth in the Functional Food Sector Gives a Hearty Boost to the Heart Health Ingredients Market
4. Hanger Orthopedic Group Welcomes Vinit Asar as Chief Growth Officer
5. Varian Medical Systems Announces Net Orders Growth Estimates for the First Quarter of Fiscal Year 2009
6. Abaxis, Inc. to Present at Sidoti & Companys Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum
7. TeleTracking Technologies to Focus on Growth
8. Cantel Medical Corp. to Present at the 11th Annual Needham Growth Stock Conference
9. Physician Staffing Trends and Hospitalist Jobs Fuel Growth at Locum Leaders
10. Abaxis, Inc. to Present at Needham & Companys Eleventh Annual Growth Stock Conference
11. Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... 2016 , ... New Brunswick, New Jersey: This year marks Children’s Specialized Hospital ... To commemorate the anniversary, the hospital has themed the milestone “Hats Off” and kicked ... Hospital Foundation on Saturday, May 21, at Johnson Park in Piscataway, New Jersey. ...
(Date:5/24/2016)... , ... (PRWEB) May ... three new members of its Advisory Board. Joining the Grow ... Kusch. “All three of them embody the mission of our organization ... very fortunate to have them as we continue to expand our ...
(Date:5/24/2016)... ... 24, 2016 , ... Boyd Industries, a leading supplier of dental chairs ... product for pediatric dentistry , at AAPD 2016, the annual conference and trade ... The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces of the ...
(Date:5/24/2016)... ... 24, 2016 , ... Eggsurance, the first independent, non-clinic related ... community and education hub for women considering fertility preservation, as well as those ... and welcoming place for women to find cycle buddies, get clinic recommendations and ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, president ... the development of technological innovations that lead to broad-based healthcare solutions. , “Jon ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... 24, 2016  NxStage Medical, Inc. (Nasdaq: ... advancing renal care, today announced that Jeffrey H. ... the following schedule of investor conferences. Where applicable, a ... http://ir.nxstage.com/ .   ... NY, NY           Friday, June 10, 2016 1:30 p.m. ...
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
Breaking Medicine Technology: